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Aim: To study the role of complement receptor 1 (CR1) for binding of Escherichia coli (E. coli) 2 
to erythrocytes, for leukocyte phagocytosis, oxidative burst and complement activation in 3 
human whole blood from a CR1 deficient (CR1D) patient and healthy controls with low, 4 
medium and high CR1 numbers.  5 
Methods: Alexa-labelled bacteria were used to quantify erythrocyte-bound bacteria, free 6 
bacteria in plasma and phagocytosis using flow cytometry. Complement activation in plasma 7 
was measured by enzyme-linked immunosorbent assay. The CR1 numbers as well as C3bc and 8 
C4bc deposition on erythrocytes were measured by flow cytometry. Cytokines were measured 9 
using multiplex technology, and bacterial growth was measured by colony forming units. CR1 10 
was blocked using the anti-CR1 blocking mAb 3D9. 11 
Results: Approximately 85% of E. coli bound to erythrocytes after 15 minutes incubation in 12 
donor blood with high and medium CR1 numbers, 50% in the person with low CR1 numbers 13 
and virtually no detectable binding in the CR1D (r2=0.87, P<0.0007). The number of free 14 
bacteria in plasma was inversely related to erythrocyte CR1 numbers (r2=0.98, P<0.0001). E. 15 
coli-induced phagocytosis and oxidative burst were significantly enhanced by the anti-CR1 16 
mAb 3D9 and in the CR1D and the donor with low CR1 numbers. E. coli-induced complement 17 
activation in plasma, C3bc and C4bc deposition on erythrocytes, and bacterial growth were 18 
similar in all four cases. Conclusions: CR1D and low CR1 numbers prevented E. coli binding 19 
to erythrocytes, increased free bacteria in plasma, phagocytosis and oxidative burst, but did not 20 
affect plasma or surface complement activation and bacterial growth.  21 
  22 
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1. Introduction 1 
Despite the wide use of antibiotics, Gram-negative sepsis still exhibits high lethality in Western 2 
countries (Gaieski, Edwards et al. 2013). Improved knowledge concerning the basal 3 
mechanisms and cells involved in sepsis-induced inflammation and organ damage is needed, 4 
as well as the role of the complement system, which is rapidly activated during sepsis (Ward 5 
2016).  6 
 7 
Gram-negative bacteria are rapidly opsonized by complement C3b, iC3b and C4b due to 8 
activation of the alternative, classical or lectin pathways (Newman and Mikus 1985, Cooper 9 
1969, Ricklin, Hajishengallis et al. 2010). This opsonization of bacteria by complement 10 
fragments facilitates binding of the bacteria to complement receptors, including CR1 (CD35) 11 
on red cells, a process named immune adherence (Birmingham and Hebert 2001). The binding 12 
of ligands to CR1 induces clustering of the receptors on the erythrocyte surface in complex with 13 
the scaffolding protein FAP-1 (Ghiran, Glodek et al. 2008). In the bloodstream, this immune 14 
adherence allows the transport of bacteria, immune complexes and opsonized cellular fragments 15 
on red cells to the sinusoids of liver and spleen (Benacerraf, Sebestyen et al. 1959, Schifferli, 16 
Ng et al. 1988, Birmingham and Hebert 2001). A complement receptor of the immunoglobulin 17 
family on liver Kupffer cells is involved in phagocytosis of the bacteria (Helmy, Katschke et 18 
al. 2006). The red blood cells then return to the circulation.  19 
 20 
CR1 is a glycoprotein receptor that is located on human erythrocytes, most leukocytes, B cells 21 
and tissue phagocytes (Birmingham and Hebert 2001). Both Gram-positive (Nelson 1953), 22 
Gram-negative bacteria (Brekke, Hellerud et al. 2011) and mannose-binding lectin (MBL) 23 
(Ghiran, Barbashov et al. 2000) may bind to erythrocyte CR1 in human whole blood. Notably, 24 
the concentration of erythrocytes is approximately 700-fold higher than the concentration 25 
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leukocytes in human whole blood and thus, the main pool of CR1 receptors in blood is on the 1 
erythrocytes. Importantly, the erythrocyte CR1 numbers vary between individuals due to 2 
genetic polymorphisms (Wong, Cahill et al. 1989) or diseases, like systemic lupus 3 
erythematosus (SLE) where CR1 is decreased (Iida, Mornaghi et al. 1982). Interestingly, the 4 
clearance of Streptococcus pneumonia in vivo in transgenic mice expressing human CR1 is 5 
enhanced compared with wild type mice lacking CR1 (Li, Wang et al. 2010). The numbers of 6 
CR1 on erythrocytes may therefore influence the degree of bacterial clearance in infections. 7 
Furthermore, malaria parasites invade red blood cells by binding to CR1 (Spadafora, Awandare 8 
et al. 2010). CR1 is also a regulator of complement activation, acting as co-factor for factor I in 9 
cleavage of C3b to iC3b and further to C3c and C3dg (Iida and Nussenzweig 1981).  10 
 11 
Phagocytosis of bacteria is facilitated by contact between the complement-opsonized bacterial 12 
surface and complement receptor 3 (CD11b/CD18) on leukocytes (Mollnes, Brekke et al. 2002, 13 
Brekke, Christiansen et al. 2007). CR1 on leukocytes, although not being a phagocytic receptor 14 
per se, is involved in the phagocytosis of bacteria, probably by participating in the initial 15 
binding of the bacteria to the leukocyte surface (Birmingham and Hebert 2001, Brekke, 16 
Hellerud et al. 2011). Bacterial structures acting as pathogen-associated molecular patterns 17 
(PAMPS) are recognized by leukocyte pattern recognition receptors (PRRs) on the cell surface 18 
and in phagosomes, including extra- and intra-cellular Toll-like receptors (TLRs), leading to 19 
cytokine release (Kawai and Akira 2010). Macrophage phagocytosis of several bacteria is also 20 
mediated by complement receptors, including CR1, and is closely linked to an enhanced 21 
interferon gamma response, which inhibits complement receptor function (Schlesinger and 22 
Horwitz 1991). Enhanced interferon gamma release has been observed in mononuclear cells 23 




The aim of the present study was to examine the role of erythrocyte CR1 numbers in the binding 1 
of Gram-negative E. coli bacteria to erythrocytes, and its consequences for free bacteria in 2 
plasma, as well as for phagocytosis, oxidative burst and cytokine release. Finally, the effect on 3 
complement activation was studied. For this purpose we took advantage of blood donors with 4 
different numbers of erythrocyte C1 numbers using a human whole blood model anticoagulated 5 
with lepirudin, since this has no adverse effects on complement activation (Mollnes, Brekke et 6 




2. Materials and methods 1 
 2 
2.1 Equipment and reagents 3 
All equipment, including polypropylene tubes (NUNC, Roskilde, Denmark) and tips used in 4 
the whole-blood experiments, was endotoxin-free. Phosphate-buffered saline (PBS) with or 5 
without Ca2+ and Mg2+ was obtained from Sigma-Aldrich (MO, USA). Lepirudin (Refludan) 6 
was obtained from Celgene (Windsor, Great Britain). The Protein G Spin Kit columns (0.2 mL) 7 
for antibody purification were obtained from Thermo Fisher Scientific (Pierce, Rockford, IL). 8 
The Burst- and Phago-test kits were both obtained from ORPEGEN Pharma (Heidelberg, 9 
Germany). LDS-751, Alexa 488, a BacLight green kit for direct fluorescent staining of 10 
unlabelled bacteria, and dimethyl sulfoxide (DMSO) were obtained from Invitrogen Molecular 11 
Probes (Eugene, OR). Zymosan A, EDTA and bovine serum albumin were all obtained from 12 
Sigma-Aldrich (St. Louis, MO). The mouse anti human CR1 blocking (clone 3D9) has been 13 
previously characterized (O'Shea, Siwik et al. 1985), and used in whole blood (Brekke, Hellerud 14 
et al. 2011), was a kind gift from Ronald P. Taylor, Univ. of Virginia, US. The isotype-matched 15 
mouse anti-human IgG1 control mAb (clone BH1) was obtained from Diatec Monoclonals AS 16 
(Oslo, Norway).  17 
 18 
2.2 Flow cytometry of CR1 on erythrocytes 19 
The number of CR1 antigenic sites on erythrocytes was analysed using flow cytometry as 20 
previously described (Pham, Kisserli et al. 2010). The CR1D blood donor had a very low CR1 21 
expression, i.e. less than 50 CR1 antigenic sites per erythrocyte (Kiss, Csipo et al. 1996), while 22 
the low, medium and high blood donors had 200, 500 and 800 antigenic sites per erythrocyte, 23 




2.3 Bacteria 1 
Escherichia coli (E. coli) LE392 strain (ATCC 33572) was obtained from the American Type 2 
Culture Collection (Manassas, VA) and was grown, washed and counted using flow cytometry 3 
as previously described (Brekke, Christiansen et al. 2007). The bacteria were harvested and 4 
washed once using Dulbecco’s phosphate-buffered saline without Ca2+ and Mg2+ (PBS) by 5 
centrifugation for 10 min at 3220 x g (4°C). Subsequently, the bacteria were aliquoted, heat-6 
inactivated for 1 hour at 60°C and stored at -80°C. A frozen ampoule was thawed at ambient 7 
temperature, washed six times with PBS and centrifuged for 10 min at 3220 x g (4°C) to remove 8 
extracellular lipopolysaccharides. Bacteria for Alexa 488 staining were separated, whereas the 9 
remainder were washed three more times. For counting, the bacteria were stained for 5 min 10 
using Syto BC (Invitrogen Molecular Probes) and counted in Truecount tubes (Becton-11 
Dickinson) using a FACScalibur or a LSRII flow cytometer with FACSDiva software (Becton-12 
Dickinson).   13 
 14 
2.4 Whole blood model of bacterial inflammation 15 
Whole blood was obtained using a standard venipuncture technique and lepirudin (50 mg/L) as 16 
anticoagulant (Mollnes, Brekke et al. 2002). The whole blood (5 volume parts) was 17 
preincubated for 5 min at 37°C in PBS (1 part) and thereafter incubated as indicated with PBS 18 
(control), cobra venom factor (CVF), heat-aggregated immunoglobulin G (HAIGG) or E. coli 19 
bacteria in PBS (1 volume part). The experiments with blood from the different blood donors 20 
were repeated on separate days.  21 
 22 
2.5 Quantitation of bacteria bound to erythrocytes and free in plasma 23 
Alexa 488-labelled E. coli bacteria bound to erythrocytes and free bacteria in plasma were 24 
quantified by flow cytometry as previously described (Brekke, Hellerud et al. 2011). Whole 25 
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blood cells were fixed with 0.25% paraformaldehyde for 4 min at 37C. To avoid coincidences 1 
of erythrocytes not carrying bacteria, samples were diluted at 1:320 using PBS and counted 2 
using Truecount tubes. Whole blood with EDTA (10 mM) served as a control since EDTA 3 
completely blocked complement activation and bacterial opsonisation (Brekke, Hellerud et al. 4 
2011). Samples were analysed using a FACSCalibur flow cytometer (Becton Dickinson), with 5 
forward scatter (FSC) and side scatter (SCC) in log mode. Threshold was set on the Alexa 6 
FLUOR® 488 channel whereby only beads, free bacteria, erythrocytes with bound bacteria and 7 
leucocytes having bound or phagocytozed bacteria were acquired. Gates were established 8 
around the beads, the erythrocytes and the free bacteria for analysis. The number of events in 9 
the erythrocyte gate and the gate for free bacteria were related to the number of beads giving 10 
an absolute count. In general RBCs binding bacteria had only one bacteria attached to the 11 
surface and this was confirmed by immunofluorescence microscopy of blood smears. To 12 
confirm that bacteria/erythrocyte conjugates were not formed due to the presence of 13 
paraformaldehyde, we performed control experiments without paraformaldehyde and obtained 14 
similar results. 15 
 16 
2.6 Phagocytosis 17 
For the phagocytosis assay, heat-inactivated E. coli (6 x 109) were washed six times as described 18 
above, and the supernatant was discarded. Subsequently, NaHCO3 (0.2 M, 600 µL, pH 8.35, 19 
sterile-filtered and heat-inactivated for 1 hour at 60°C) was added together with 6 µL of Alexa 20 
FLUOR® 488 carboxylic acid succinimidyl ester (10 g/L) in dimethyl sulfoxide (DMSO). The 21 
tube was packed in tinfoil and rotated for 1 hour at ambient temperature. Bacteria were washed 22 
three times with PBS, centrifuged for 5 min at 8000 x g, resuspended in PBS and counted as 23 
described above. Phagocytosis of Alexa-labelled heat-inactivated E. coli bacteria was analysed 24 
by flow cytometry and expressed as the median fluorescence intensity (MFI) or percent (%) 25 
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positive cells. In brief, Alexa-labelled bacteria were added to human whole blood and further 1 
incubated for 20 min. at 37°C. 2 
  3 
2.8 ELISA for complement proteins and activation products 4 
Plasma C4bc, C1rs-C1-inhibitor complexes, C3bBbP, C3bc and the terminal complement 5 
complex (TCC) were analysed by ELISA as previously described (Bergseth, Ludviksen et al. 6 
2013). A sample of pooled human sera from healthy donors activated with zymosan (10 7 
mg/mL) was used as the standard and set to 1000 arbitrary units (AU/mL). The functional 8 
activity of the classical pathway (CP) and alternative pathway (AP) in serum were analysed by 9 
Wielisa® (Life Science AB, Malmø, Sweden). Total C3 and C4 in serum were analysed on a 10 
Siemens BN ProSpec® nephelometer using reagents from Siemens (Siemens Healthcare 11 
Diagnostics Ltd, Camberley, UK).  12 
 13 
2.9 Flow cytometric analysis of IgG, C3bc and C4bc opsonization  14 
HAIGG or CVF was added to whole blood and incubated for 30 min (37ºC). Unopsonized E. 15 
coli were added to lepirudin plasma obtained from whole blood after centrifugation for 15 min 16 
at 3220 x g (4oC). Five µL of blood (HAIGG or CVF) or plasma with E. coli bacteria were then 17 
washed twice with PBS and centrifuged for 15 min at 3220 x g (4oC) and resuspended in PBS 18 
containing 0.1% (w/v) BSA. IgG, C3bc and C4bc opsonization was analysed using rabbit anti-19 
human IgG (Dako F0056) and isotype control (Dako X0929), FITC-conjugated rabbit anti-20 
human C3c which also recognize C3b (Dako F0201) and rabbit anti-human C4c mAbs, 21 
respectively (Brekke, Christiansen et al. 2007). FITC-conjugated rabbit anti-mouse Ig (Dako 22 
F0261) was used as a control. The results are expressed as the median fluorescence intensity 23 




2.10 Bacterial growth  1 
Bacterial growth in whole blood was measured using standard microbiological techniques. In 2 
brief, live E. coli bacteria were added to fresh human whole blood in PBS, or in the presence 3 
of ant-CR1 blocking mAb 3D9 (4 µg/mL) or an isotype control mAb (4 µg/mL) and incubated 4 
for the times indicated. At the time points indicated, an aliquot of blood was redrawn and diluted 5 
in PBS. The blood (1 µL) was then spread on lactose agar plates, and bacterial growth was 6 
estimated after an overnight incubation in an air incubator at 37°C. Bacterial growth is 7 
presented as colony forming units (CFU/mL). 8 
 9 
2.11 Cytokine analysis 10 
Cytokines in EDTA plasma were analysed using the Bio-Plex human 27-plex kit from Bio-Rad 11 
Laboratories (Hercules, CA). The following cytokines were analysed: interleukin (IL)-1 beta 12 
(IL-1β), IL-1 receptor antagonist (IL-1RA), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (C-X-C motif 13 
chemokine ligand 8; CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, monocyte 14 
chemoattractant protein 1 (MCP-1 or CCL2), macrophage inflammatory protein-1-alpha 15 
(MIP-1α or CCL3), macrophage inflammatory protein-1-beta (MIP-1β or CCL4), eotaxin-1 16 
(C-C motif chemokine ligand 11; CCL11), interferon-γ-inducing protein 10 or IP-10 17 
(CXCL10), basic fibroblast growth factor (FGF-basic), granulocyte colony stimulating factor 18 
(G-CSF), granulocyte–macrophage colony stimulating factor (GM-CSF), interferon gamma 19 
(IFN-γ), platelet-derived growth factor-BB (PDGF-BB), RANTES (CCL5), tumour necrosis 20 
factor (TNF) and vascular endothelial growth factor (VEGF). The samples were analysed using 21 
a Bio-Plex 200 instrument from Bio-Rad.  22 
 23 
2.12 Statistical analysis 24 
11 
 
The experiments were performed with each blood donor on two separate days, and the results 1 
are expressed as the means ± range. Non-linear and linear regression analysis on the means of 2 
data from the CR1D, the person with low, medium and high erythrocyte CR1 numbers (n=4) 3 
of duplicate measurements were performed using GraphPad Prism version 6.0 (GraphPad 4 
Software, San Diego, CA). The CFU results after adding the anti-CR1 blocking mAb were 5 
analyzed using Student`s T-test.   6 
 7 
2.13 Ethics 8 
The study was approved by the Regional ethics committee in the Northern Health Region of 9 
Norway and written informed consent was obtained from the blood donors. 10 
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3 Results 1 
 2 
3.1 Effect of erythrocyte CR1 numbers on the binding of E. coli bacteria to erythrocytes 3 
and free bacteria in plasma in fresh human whole blood  4 
The role of erythrocyte CR1 numbers for binding of E. coli to erythrocytes and the number of 5 
free bacteria in plasma were examined in fresh human whole blood (Fig. 1). The CR1D blood 6 
donor showed barely any binding of bacteria to erythrocytes (Fig 1A), whereas this donor 7 
showed very high numbers of free bacteria in plasma (Fig. 1D). In the blood donor with low 8 
CR1 numbers, 42% of the bacteria were bound to erythrocytes at the highest bacterial 9 
concentration assessed (108 E. coli/mL) (Fig. 1A), and 40% of the bacteria were free in plasma 10 
(Fig. 1D). In the blood donors with medium and high CR1 erythrocyte numbers, 80-90% of the 11 
bacteria were bound to erythrocytes (Fig. 1A). In these blood donors, less than 5% of the 12 
bacteria were free in plasma (Fig. 1D). EDTA, chelating calcium and magnesium and efficiently 13 
blocking complement activation, completely abolished the binding of E. coli bacteria to 14 
erythrocytes in all donors (Fig. 1A) and virtually all bacteria were detected free in plasma (Fig. 15 
1D). The numbers of E. coli bacteria bound to erythrocytes were significantly and positively 16 
correlated (r2= 0.87, P<0.0007) with the log10 of erythrocyte CR1 numbers when analysed 17 
using linear regression (Fig. 1C). Similarly, the numbers of E. coli bacteria free in plasma were 18 
significantly and negatively correlated (r2=0.98, P<0.0001) with the log10 of erythrocyte CR1 19 
numbers when analysed using linear regression (Fig. 1F).  20 
 21 
3.2 Effect of erythrocyte CR1 numbers on E. coli-induced phagocytosis in fresh human 22 
whole blood 23 
The role of erythrocyte CR1 numbers in granulocyte and monocyte phagocytosis of E. coli 24 
bacteria was then examined (Fig. 2). Phagocytosis of E. coli was analysed by flow cytometry 25 
13 
 
and presented as the median fluorescence intensity (MFI, Fig. 2). The blood donor with low 1 
erythrocyte CR1 numbers and CR1D on erythrocytes had the highest granulocyte phagocytosis 2 
measured as MFI (Fig. 2A), and monocyte phagocytosis measured as MFI (Fig. 2D). In 3 
comparison, the blood donor with medium and high CR1 numbers had the lowest phagocytosis 4 
in granulocytes (Fig. 2A) and monocytes (Fig. 2D). The granulocyte phagocytosis were 5 
negatively and significantly correlated (r2= 0.49, P<0.05) with the log10 of the erythrocyte CR1 6 
numbers when analysed using linear regression (Fig. 2C). The phagocytosis in monocytes were 7 
similarly negatively and significantly correlated (r2= 0.51, P=0.046) with the log10 of 8 
erythrocyte CR1 numbers (Fig. 2F). 9 
 10 
3.3 Effect of erythrocyte CR1 numbers on E. coli-induced oxidative burst in fresh human 11 
whole blood 12 
We next examined the granulocyte and monocyte oxidative burst using flow cytometry (Fig. 13 
3). The E. coli-induced oxidative burst in granulocytes (Fig. 3A) and monocytes (Fig. 3D) was 14 
most enhanced in blood from the CR1D and the donor with low erythrocyte CR1 numbers. The 15 
blood donors with medium and high erythrocyte CR1 numbers exhibited similar and lower 16 
oxidative burst (Fig. 3). The E. coli-induced granulocyte oxidative burst were negatively and 17 
significantly correlated (r2= 0.73, P = 0.0066) with the log10 of erythrocyte CR1 numbers when 18 
analysed using linear regression (Fig. 3C). The oxidative burst in monocytes were similarly 19 
negatively and significantly correlated (r2= 0.72, P = 0.008) with the log10 of erythrocyte CR1 20 
numbers (Fig. 3F).  21 
 22 
3.4 The effect of erythrocyte CR1 numbers on E. coli-induced complement activation in 23 
the fluid phase 24 
14 
 
To examine the role of erythrocyte CR1 numbers on complement activation in the fluid phase, 1 
we incubated fresh human whole blood with E. coli and measured plasma complement 2 
activation products in the four blood donors. As expected, E. coli activated complement as 3 
detected by C4bc (classical and lectin pathway), C3bBbP (alternative pathway), C3bc (all 4 
pathways) and TCC (sC5b-9; terminal pathway) in the fluid phase (Fig. 4A-D). Although the 5 
blood donor with low CR1 numbers had the highest complement activation in the fluid phase 6 
for all activation products, and particularly for C4bc, CR1D showed complement activation in 7 
the fluid phase close to the donors with medium and high erythrocyte CR1 numbers. These 8 
findings indicated that the E. coli-induced complement activation in the fluid phase was not 9 
significantly affected by erythrocyte CR1 numbers.  10 
 11 
3.5 Effect of erythrocyte CR1 numbers on cobra venom factor and heat-aggregated 12 
immunoglobulin G (HAIGG)-induced complement activation  13 
 14 
No correlations were found between plasma C4bc, C3bc, C3bBbP and TCC levels  and different 15 
erythrocyte CR1 numbers after activating whole blood with CVF and HAIGG (Fig. 5). The 16 
functional activity of the CP and AP in serum from the different blood donors were within 17 
normal limits (Fig. 5E,F). However, the donor with low CR1 numbers had the highest CP and 18 
AP activity. Similarly, the erythrocyte deposition of IgG, C3bc and C4bc were similar after 19 
activating whole blood from donors with different CR1 numbers with CVF or HAIGG 20 
(Supplementary Fig. 1). The positive control E. coli bacteria showed significant opsonization 21 
with IgG, C4c and C3c as expected (Supplementary Fig. 1). The total C3 and C4 levels in 22 




3.6 Effect of erythrocyte CR1 numbers on cobra venom factor and HAIGG-induced 1 
complement activation  2 
The effect of erythrocyte CR1 numbers on PBS, CVF- and HAIGG-induced complement 3 
activation on the surface on red blood cells were then examined (Fig. 6). Erythrocyte-bound 4 
IgG, C3c and C4c were analysed using flow cytometry and expressed as MFI. Since the 5 
fluorescence of the isotype control was the same, no detectable IgG, C3c or C4c deposition on 6 
these RBCs were detected. CR1D patient showed the same binding of IgG, C3c and C4c on 7 
erythrocytes after addition of PBS, CVF and HAIGG as the donors with low, medium and high 8 
erythrocyte CR1 numbers (Fig. 6). As expected, the positive control E. coli bacteria showed 9 
enhanced IgG, C3c and C4c deposition after 30 min incubation.   10 
 11 
3.7 Effect of erythrocyte CR1 numbers on bacterial growth in human whole blood 12 
We then examined the effect of erythrocyte CR1 numbers on bacterial growth in human whole 13 
blood (Fig. 7A). Live E. coli bacteria were added to fresh human whole blood from blood 14 
donors with high and absent erythrocyte CR1 and bacterial growth measured as colony forming 15 
units (CFU/mL). When the E. coli bacteria were added to a PBS control, the CFU count was 16 
stable at all time points (Fig. 7A). In comparison, the CFU decreased with increasing incubation 17 
time when the bacteria were added to human blood with high CR1 numbers. However, the 18 
absence of erythrocyte CR1 in the CR1D had no influence on E. coli growth in whole blood. 19 
Similarly, when the anti-CR1 blocking mAb 3D9 was added to increasing concentrations of 20 
live E. coli (1 x 106, 1 x 107/mL and 1 x 108/mL) in donors with high CR1 numbers, no effect 21 
on bacterial growth was found (Fig. 7B).  22 
 23 
3.8 Effect of the anti-CR1 blocking mAb on the binding of E. coli to erythrocytes, free 24 
bacteria in plasma, phagocytosis and oxidative burst  25 
16 
 
The anti-CR1 blocking mAb 3D9 efficiently reduced the binding of E. coli to erythrocytes, 1 
increased the number of free bacteria in plasma, phagocytosis and oxidative burst in monocytes 2 
(Fig. 8). In comparison, an isotype matched control mAb had no effect (Fig. 8), in line with 3 
previous results (Brekke, Hellerud et al. 2011).  4 
 5 
  6 
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 Discussion 1 
The present results indicate that erythrocyte CR1 numbers significantly affect the binding of E. 2 
coli bacteria to erythrocytes and strongly affects the amount of free bacteria in plasma, with 3 
subsequent consequences for phagocytosis and bacteria-induced oxidative burst. Collectively 4 
these results support a relation between phagocytosis and oxidative burst. The erythrocytes 5 
from the CR1D donor, nature’s own human knock-out, bound only very small amounts of E. 6 
coli bacteria. Since this clonal CR1D in erythrocytes is extremely rare, these “lessons from 7 
nature” experiments should be interpreted with caution. Despite only one CR1 deficient 8 
individual could be examined, the addition of donors with different amounts of CR1 on their 9 
erythrocytes gave substantial support to our conclusions, since linear regression analyses 10 
between the readouts and the number of erythrocyte CR1 molecules could be calculated.  11 
 12 
Leukocyte phagocytosis of E. coli bacteria was increased in CR1D compared with the other 13 
donors. Since the binding of bacteria to erythrocytes was significantly lower in CR1D and in 14 
the donor with low CR1 numbers, we speculate that this reduced binding of E. coli to 15 
erythrocytes, leading to a marked increase in free bacteria in plasma, increased the availability 16 
of bacteria for leukocyte phagocytosis. This was supported by the effect of the anti-CR1 17 
blocking mAb which decreased the number of E. coli on erythrocytes, increased free bacteria 18 
in plasma, phagocytosis and oxidative burst in monocytes. This hypothesis has been confirmed 19 
in a previous study by addition of a blocking mAb to CR1, which resulted in an increased 20 
number of free bacteria in plasma and enhanced phagocytosis and oxidative burst in 21 
granulocytes (Brekke, Hellerud et al. 2011). Binding of E. coli to erythrocyte CR1 therefore 22 
restricts the uptake of bacteria in leukocytes similarly to the reduced uptake of immune 23 
complexes mediated by erythrocyte CR1 binding (Nielsen, Matthiesen et al. 1997). E. coli-24 
induced phagocytosis and oxidative burst in human whole blood are closely related events 25 
18 
 
involving complement C5a formation and uptake through complement receptor 3 (Mollnes, 1 
Brekke et al. 2002). The number of erythrocytes in human whole blood exceeds the number of 2 
leukocytes by approximately 700 times. Thus, C3b and C4b-opsonized bacteria will initially 3 
mainly bind to erythrocyte CR1 (Nelson 1953, Brekke, Hellerud et al. 2011). Similarly, the 4 
number of CR1 molecules on each erythrocyte in human blood is approximately four-fold 5 
higher than those on a leukocyte, further increasing the total amount of erythrocyte CR1 as 6 
compared to leukocyte population (Fearon 1980). The number of erythrocyte CR1 molecules  7 
in Caucasians vary from about 150 to 1200 per erythrocytes due to genetic polymorphisms 8 
(Pham, Kisserli et al. 2010).   9 
 10 
Thus, our data support the notion that CR1 has an important role in the initial binding of bacteria 11 
to erythrocytes, and that this binding probably affects the distribution of bacteria and other iC3b 12 
opsonized molecules in vivo (Atkinson, Chan et al. 1988). Previous data have indicated that 13 
CR1 binding may affect the distribution of bound immune complexes from spleen to the liver 14 
(Atkinson, Chan et al.  1988, Klein, Zhadkewich et al. 1994). To explore these mechanisms in 15 
detail in the future, experiments with Gram-negative bacteria could be performed in a CR1 16 
knock-in model with human CR1 on mouse erythrocytes (Li, Wang et al. 2010). In particular, 17 
the distribution of different bacteria between organs could be interesting to examine in such a 18 
knock-in model. However, a limitation of mouse models is the occurrence of another different 19 
complement receptor encoded by the complement receptor-related gene Y (CrrY), which has 20 
complement inhibitory actions (Quigg, Kozono et al. 1998) and is not present in humans (Naik, 21 
Sharma et al. 2013).  22 
 23 
This report indicates, for the first time, that CR1 erythrocyte numbers does not affect the 24 
degree of complement activation induced in the fluid phase by various complement activators 25 
19 
 
like E. coli, HAIGG and CVF. The donor with low CR1 numbers had the highest CP and AP 1 
activity, but the CP and AP activity in serum was as expected not related to erythrocyte CR1 2 
numbers. Although CR1 is a well-established complement regulator, acting as cofactor for 3 
cleavage of C4 and C4 controlling the complement activation at the level of C3 (Iida and 4 
Nussenzweig 1981), and soluble CR1 is an efficient inhibitor of C3 activation (Atkinson, 5 
Chan et al.) (Fearon 1979), our data indicate that the number of CR1 on erythrocytes does not 6 
affect the degree of fluid phase complement activation. Thus, deficiency of CR1 on 7 
erythrocytes does not lead to an uncontrolled complement activation, neither at basal level nor 8 
when activation is induced by external activators.  9 
 10 
No detectable IgG, C3c or C4c deposition on the erythrocytes were detected after stimulation 11 
with CVF and HAIGG. The lack of an effect of CR1 numbers on C3c, C4c and IgG deposition 12 
on the erythrocyte cell surface probably reflects that the erythrocyte prevents complement 13 
attack by other regulators, including the decay-accelerating factor (DAF) on the erythrocyte 14 
surface (Hourcade, Liszewski et al. 2000). Furthermore, HAIGG-induced complement 15 
activation probably occurs on the surface of HAIGG particles, i.e., on particles a certain 16 
distance away from erythrocyte CR1. Furthermore, since only a few E. coli bacteria initially 17 
bound to CR1D erythrocytes, complement activation on the E. coli surface probably did not 18 
occur in close proximity to the few CR1 receptors still present on CR1D erythrocytes.  19 
 20 
Next, we examined the effect of erythrocyte CR1 binding on bacterial growth in whole blood. 21 
We used a complement-sensitive strain E. coli strain, explaining the rapid decrease in CFU after 22 
addition of live E coli to fresh human whole blood. However, bacterial growth did not differ in 23 
blood from CR1D compared with blood from a person with high CR1 numbers. This result was 24 
further confirmed using a blocking mAb against human CR1 at several bacterial concentrations. 25 
20 
 
The results indicated that the growth of E. coli was not affected by the number of CR1 on the 1 
erythrocytes. 2 
 3 
The E. coli-induced release of inflammatory cytokines were not affected by the number of 4 
erythrocyte CR1. The hypothesis for the cytokine assays was that since the CR1 erythrocyte 5 
numbers significantly affected the number of free bacteria in plasma and leucocyte 6 
phagocytosis, the release of cytokines could be affected. These data may indicate that although 7 
the initial phagocytosis was increased in CR1D, bacterial pathogen associated molecular 8 
patterns (PAMPs), such as lipopolysaccharides, that participate in cytokine release are probably 9 
released and bind to Toll-like receptor 4 (TLR4) on leukocytes both when bacteria are bound 10 
to CR1 and when they are free in plasma. The TLR4 co-receptor CD14 and complement 11 
activation play an important role in the E. coli-induced cytokine release in vivo (Thorgersen, 12 
Pharo et al. 2009). However, the levels of several cytokines in the baseline sample were 13 
increased substantially increased in CR1D. This was particularly pronounced for IL-1RA and 14 
IFN-γ. These data should be interpreted with great caution and might not be due to an direct 15 
effect of low erythrocyte CR numbers, but rather due to a generally increased cytokine release 16 
caused by the SLE-like inflammatory disease in this individual, in agreement with a previous 17 
report (Csiszar, Nagy et al. 2000).  18 
 19 
The human whole blood model of sepsis used in this study has some limitations in comparison 20 
to the in vivo situation, including a lack of endothelial cells. In addition, the model lacks 21 
physiological blood flow, although the tubes are gently rotated. However, this model of 22 
bacterial-induced complement activation and inflammation is currently to our knowledge the 23 
best in vitro model to study the role of complement in whole blood since lepirudin do not affect 24 




In conclusion, the CR1 numbers on erythrocytes significantly affect the binding of E. coli to 2 
erythrocytes and the number of free bacteria in plasma, with subsequent consequences for 3 
leukocyte phagocytosis and oxidative burst in fresh human whole blood. The results indicate 4 
that individuals with low erythrocyte CR1 numbers may be predisposed to an enhanced initial 5 
leukocyte response after exposure to bacteria in blood. Whether this phenomenon plays a role 6 




This study was financially supported by The Norwegian Council on Cardiovascular Disease, 2 




Legends to figures 2 
Fig. 1.  3 
Effect of erythrocyte complement receptor 1 (CR1) numbers on E. coli binding to erythrocytes 4 
(A,B,C) and free bacteria in plasma (D,E,F). Increasing concentrations of heat inactivated E. 5 
coli were added to fresh human whole blood from the CR1 deficient (CRID) donor (< 50 6 
CR1/erythrocyte: open triangle up) and from donors with low (200 CR1/erythrocyte: open 7 
circle), medium (500 CR1/erythrocytes: open square) and high (800/CR1 /erythrocyte: open 8 
triangle down) CR1 numbers. The legends to symbols are indicated in panel A, and are the same 9 
in Fig. 1-4. As a control, EDTA (10 mM final concentration) was added to the same blood 10 
donors (filled symbols). The number of erythrocytes with bound E. coli (A,B,C), and bacteria 11 
free in plasma (D,E,F) were analysed by flow cytometry after 10 min incubation at 37°C. The 12 
results are expressed as 108 bacteria/mL and are presented as the means ± range. Correlation 13 
between erythrocyte CR1 numbers and (B) the mean number of erythrocytes with bound E. coli 14 
against erythrocyte CR1 numbers using non-linear regression analysis and the log10 of 15 
erythrocyte CR1 numbers using linear regression analysis (C) were performed. The mean 16 
number of bacteria bound on erythrocytes were non-linearly correlated with erythrocyte CR1 17 
numbers (B), following the equation Y = -0.02479 + 0.002758X – 0.000001955X2 (r2=0.88) 18 
when analysed using polynomial second order non-linear regression. The mean  number of 19 
bacteria on erythrocytes were linearly correlated with the log10 of erythrocyte CR1 numbers 20 
(C) (r2 = 0.87, P < 0.0007). The number of free bacteria in plasma was non-linearly correlated 21 
with erythrocyte CR1 numbers analysed using non-linear regression analysis (E), and following 22 
the equation Y = 0.8581 - 0.002651X + 0.000002013X2 (r2=0.999) when analysed using 23 
polynomial second order non-linear regression. The log10 of erythrocyte CR1 numbers was 24 
24 
 
linearly correlated with the mean number of free E. coli (F) in plasma (r2 = 0.98, P < 0.0001) 1 




Fig. 2.  6 
Effect of erythrocyte CR1 numbers on E. coli phagocytosis in granulocytes (A,B,C) and 7 
monocytes (E,F,G). Increasing concentrations of Alexa-labelled heat-inactivated E. coli were 8 
added to fresh human whole blood from the CR1 deficient donor (CR1D: triangle up), and from 9 
donors with low (circle), medium (square) and high CR1 numbers (triangle down). 10 
Phagocytosis in granulocytes and monocytes was analysed after a 20-min incubation at 37°C 11 
using flow cytometry. The results are expressed as the median fluorescence intensity (MFI) and 12 
presented as the means ± range. The granulocyte (B) and monocyte phagocytosis (E) was non-13 
linearly correlated with erythrocyte CR1 numbers analysed using non-linear regression analysis 14 
(B,E). The polynomial second order non-linear regression in panel B followed the equation Y 15 
= 84794 – 29.98X + 0.04115X2 (r2=0.75). The log10 of CR1 numbers were significantly and 16 
linearly related with the (C) granulocyte phagocytosis (r2 = 0.49, P = 0.05) and (F) monocyte 17 
phagocytosis (r2 = 0.51, P = 0.046) analysed using linear regression analysis in GraphPad Prizm 18 
(n=4). The polynomial second order non-linear regression of the data in panel E followed the 19 
equation Y = 73554 – 75.24X + 0.02921 X2 (r2=0.65). 20 
 21 
Fig. 3.  22 
Effect of erythrocyte CR1 numbers on E. coli-induced oxidative burst in granulocytes (A) and 23 
monocytes (C). Increasing concentrations of heat-inactivated E. coli were added to fresh human 24 
whole blood from the donor with CR1 deficiency (CR1D, triangle up), and from donors with 25 
25 
 
low (circle), medium (square) and high (triangle down) CR1 numbers. The oxidative burst in 1 
granulocytes and monocytes was analysed after a 10-min incubation at 37°C using flow 2 
cytometry and expressed as the median fluorescence intensity (MFI). The results are presented 3 
as the means ± range (n=4, in duplicates). The polynomial second order non-linear regression 4 
of the data in panel B followed the equation Y = 13920 – 36.17X + 0.03086 X2 (r2=0.79). The 5 
log10 of erythrocyte CR1 numbers were significantly and linearly correlated with the mean (C) 6 
granulocyte oxidative burst (r2 = 0.73, P = 0.0066) and (F) monocyte oxidative burst (r2 = 0.72, 7 
P = 0.008) analysed using linear regression analysis in GraphPad Prizm (n=4). The polynomial 8 
second order non-linear regression analysis of the data in panel E followed the equation Y = 9 
4670 – 13.13X + 0.01146 X2 (r2=0.75). 10 
 11 
Fig. 4.  12 
Effect of erythrocyte CR1 numbers on E. coli-induced complement activation in plasma. 13 
Increasing concentrations of E. coli were added to whole blood from the CR1 deficient donor 14 
(open triangle up) and from donors with low (open circle), medium (open square) and high 15 
(open triangle down) CR1 numbers, and further incubated for 30 min at 37°C. As a control, 16 
EDTA (10 mM final concentration) was added to the same blood donors (filled symbols). The 17 
following complement activation products were measured in plasma using ELISA: (A) C4bc, 18 
(B) C3bc, (C) C3bBbP and (D) the soluble terminal complement complex (TCC). The results 19 
are expressed as arbitrary units/mL (AU/mL) and presented as the means ± range.  20 
 21 
Fig. 5.  22 
Effect of erythrocyte CR1 numbers on complement activation in the fluid phase in fresh human 23 
whole blood after stimulation with cobra venom factor (CVF) and heat-aggregated 24 
immunoglobulin G (HAIGG). Phosphate-buffered saline (PBS), CVF (2.5 U/mL) and HAIGG 25 
26 
 
(0.1 and 1.0 g/L) were added to fresh human blood from the donor with CR1 deficiency (CR1D) 1 
(open bars) and from donors with low (grey bars), medium (hatched bars) and high (black bars) 2 
CR1 numbers, and further incubated for 30 min at 37ºC. (A) C4bc, (B) C3bBbP, (C) C3bc and 3 
(D) the terminal complement complex (TCC) were analysed by ELISA. The baseline sample 4 
(T0) at time zero contained EDTA and indicates basal levels. The results are expressed as 5 
arbitrary units/mL (AU/mL) and presented as the means ± range. (E) The functional activity of 6 
the classical pathway (CP) and alternative pathway (AP) were analysed by Wielisa® and 7 
expressed as percent. The dashed lines in panels E and F indicates the upper reference ranges 8 
of the assay.  9 
 10 
Fig. 6.  11 
Effect of erythrocyte CR1 numbers on (A) IgG, (B) C3c and (C) C4c deposition on erythrocytes 12 
in human whole blood analysed using flow cytometry. Phosphate-buffered saline (PBS), cobra 13 
venom factor (CVF, 2.5 U/mL) and heat-aggregated immunoglobulin (HAIGG, 0.1 and 1.0 14 
g/L) were added to fresh human blood from the donor with CR1 deficiency (CR1D) (open bars) 15 
and from the donors with low (grey bars), medium (hatched bars) and high (black bars) CR1 16 
numbers, and further incubated for 30 min at 37°C. E. coli (1 x 108/mL) was added as a positive 17 
control. The results are expressed as the median fluorescence intensity (MFI). Data are 18 
presented as the means ± range. 19 
 20 
Fig. 7.  21 
Effect of erythrocyte CR1 numbers on bacterial growth in human whole blood. (A) Live E. coli 22 
were added to human whole blood (1 x 108/mL) from the donor with CR1 deficiency (CR1D) 23 
(triangle up) and from the donor with high (triangle down) erythrocyte CR1 numbers, and 24 
further incubated up to 30 min at 37°C. As a control, live bacteria were added to PBS only 25 
27 
 
(open circle). Bacterial growth was analysed using a standard bacterial culture technique and 1 
expressed as colony forming units (CFU/mL). The results are presented as the means ± range. 2 
The anti-CR1 blocking mAb 3D9 (4 µg/mL) was added to increasing concentrations of live E. 3 
coli (1 x 106, 1 x 107/mL and 1 x 108/mL) in donors with high CR1 numbers and compared with 4 
the isotype matched control mAb (Fig. 6B). The results are presented as the means ± SD. The 5 
results in Fig. 6B was analyzed using Student`s T-test.  6 
 7 
 8 
Fig. 8.  9 
Effect of the anti-CR1 blocking mAb 3D9 on E. coli binding to erythrocytes (A), free E. coli in 10 
plasma (B), monocyte phagocytosis (C) and monocyte oxidative burst (D). The number of 11 
erythrocytes with bound E. coli (A), and bacteria free in plasma (B) were analyzed by flow 12 
cytometry after 10 min incubation at 37°C. Phagocytosis were analysed by flow cytometry and 13 
expressed as median fluorescence intensity (MFI). Oxidative burst was analysed by flow 14 
cytometry and expressed as MFI (percent of the E. coli + PBS control which was set to 100%). 15 
The anti-CR1 blocking mAb 3D9 (4 µg/mL) was added without or with E. coli (0.72 x 108/mL) 16 
and compared with the isotype matched control mAb. The results are from independent 17 
experiments with healthy blood donors (n=3-6). *P<0.05 analyzed by repeated-measures 18 
ANOVA and using the sample with E. coli + PBS as control.     19 
 20 
  21 
  22 
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Supplementary Results and Figures:  1 
“Effect of erythrocyte CR1 numbers on the plasma cytokine levels 2 
We then examined the basal plasma levels of 27 cytokines and their response to E. coli 3 
incubation in fresh whole blood. Twenty of the cytokines either had detectable basal levels 4 
and/or responded with increased release when incubated with E. coli (Supplementary Fig. 1, 5 
2,3,4). In general, there was no differences in responses to E. coli dependent on the erythrocyte 6 
CR1 numbers, whereas the following 10 cytokines were remarkably higher in the baseline 7 
plasma sample in the CR1D donor than in the other three donors: IL-1RA, IL-2, IL-4, IL-9, IL-8 
12 (p70), IL-13, IL-15, eotaxin, GM-CSF and IFN-γ (Supplementary Fig. 1,2,3,4). 9 
Quantitatively, IL-1RA (Suppl. Fig. 1B) and IFN-γ (Suppl. Fig. 2F) were the two most 10 
prominent, reaching ng/mL levels in the baseline sample in CR1D whereas hardly detectable in 11 
the other donors.”  12 
Legends to supplementary Fig.:   13 
Supplementary Fig. 1 14 
“Effect of erythrocyte complement receptor 1 (CR1) numbers on E. coli-induced (A) 15 
Interleukin (IL-1)β, (B) IL-1RA, (C) IL-6, (D) IL-8, (E) tumor necrosis factor (TNF) and (F) 16 
IL-10 levels. The cytokine levels in the baseline sample are indicated as T0. Phosphate buffered 17 
saline (T2) and different concentrations of heat-inactivated E. coli were added to fresh human 18 
whole blood from the donor with CR1 deficiency (CR1D) (open bars) and from donors with 19 
low (grey bars), medium (hatched bars) and high (black bars) CR1 numbers, and further 20 
incubated for 2 hours (T2) at 37°C. Thereafter, plasma was harvested, and the cytokines were 21 
analysed using multiplex technology. The results are expressed as pg/mL and presented as the 22 
means ± range.” 23 
Supplementary Fig. 2 24 
29 
 
“Effect of erythrocyte complement receptor 1 (CR1) numbers on E. coli-induced (A) FGF-1 
basic, (B) eotaxin, (C) G-CSF, (D) GM-CSF, (E) VEGF and (F) IFN-γ. The cytokine levels in 2 
the baseline sample are indicated as T0. Phosphate buffered saline (T2) and different 3 
concentrations of heat-inactivated E. coli were added to fresh human whole blood from the 4 
donor with CR1 deficiency (CR1D) (open bars) and from the donors with low (grey bars), 5 
medium (hatched bars) and high (black bars) CR1 numbers, and further incubated for 2 hours 6 
(T2) at 37°C. Thereafter, plasma was harvested, and the cytokines were analysed using 7 
multiplex technology. The results are expressed as pg/mL and presented as the means ± range.” 8 
 9 
Supplementary Fig. 3 10 
Effect of erythrocyte complement receptor 1 (CR1) numbers on E. coli-induced (A) Interleukin 11 
(IL)-2, (B) IL-5, (C) IL-9, (D) IL-12 (p70), (E) IL-13 and (F) IL-15 levels. The cytokine levels 12 
in the baseline sample are indicated as T0. Phosphate buffered saline (T2) and  different 13 
concentrations of heat-inactivated E. coli were added to fresh human whole blood from the 14 
donor with CR1 deficiency (CR1D) (open bars) and from donors with low (grey bars), medium 15 
(hatched bars) and high (black bars) CR1 numbers, and further incubated for 2 hours at 37°C. 16 
Thereafter, plasma was harvested, and the cytokines were analysed using multiplex technology. 17 
The results are expressed as pg/mL and presented as the means ± range.  18 
 19 
Supplementary Fig. 4. Effect of erythrocyte complement receptor 1 (CR1) numbers on E. coli-20 
induced (A) IP-10 and (B) Interleukin (IL)-17 levels. The cytokine levels in the baseline sample 21 
are indicated as T0. Phosphate buffered saline (T2) and different concentrations of heat-22 
inactivated E. coli were added to fresh human whole blood from the donor with CR1 deficiency 23 
(CR1D) (open bars) and from donors with low (grey bars), medium (hatched bars) and high 24 
(black bars) CR1 numbers, and further incubated for 2 hours at 37°C. Thereafter, plasma was 25 
30 
 
harvested, and the cytokines were analysed using multiplex technology. The results are 1 
expressed as pg/mL and presented as the means ± range. 2 
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